JP2020203844A - 不全角化抑制剤 - Google Patents
不全角化抑制剤 Download PDFInfo
- Publication number
- JP2020203844A JP2020203844A JP2019111985A JP2019111985A JP2020203844A JP 2020203844 A JP2020203844 A JP 2020203844A JP 2019111985 A JP2019111985 A JP 2019111985A JP 2019111985 A JP2019111985 A JP 2019111985A JP 2020203844 A JP2020203844 A JP 2020203844A
- Authority
- JP
- Japan
- Prior art keywords
- procyanidin
- quince
- extract
- parakeratosis inhibitor
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 33
- 208000005775 Parakeratosis Diseases 0.000 title claims abstract description 32
- XFZJEEAOWLFHDH-NFJBMHMQSA-N Epicatechin-(4beta->8)-catechin Natural products C1([C@@H]2[C@H](O)[C@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=CC(O)=C3C[C@H]([C@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-NFJBMHMQSA-N 0.000 claims abstract description 46
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims abstract description 38
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 claims abstract description 31
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims abstract description 23
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 claims abstract description 23
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 20
- 229920000385 Procyanidin B1 Polymers 0.000 claims abstract description 16
- 229920002350 Procyanidin B2 Polymers 0.000 claims abstract description 16
- XFZJEEAOWLFHDH-UKWJTHFESA-N procyanidin B1 Chemical compound C1([C@@H]2[C@H](O)[C@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=CC(O)=C3C[C@@H]([C@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UKWJTHFESA-N 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 claims abstract description 8
- 235000017788 Cydonia oblonga Nutrition 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 241001507760 Chaenomeles sinensis Species 0.000 abstract description 2
- 235000017831 Pseudocydonia sinensis Nutrition 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 102000004958 Caspase-14 Human genes 0.000 description 13
- 108090001132 Caspase-14 Proteins 0.000 description 13
- 230000000694 effects Effects 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 8
- 229940069774 quince extract Drugs 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000000434 stratum corneum Anatomy 0.000 description 6
- 230000004888 barrier function Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 4
- 229960005084 calcitriol Drugs 0.000 description 4
- 235000020964 calcitriol Nutrition 0.000 description 4
- 239000011612 calcitriol Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 102100028314 Filaggrin Human genes 0.000 description 3
- 101710088660 Filaggrin Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 230000003780 keratinization Effects 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 208000001126 Keratosis Diseases 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000001151 other effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 210000000498 stratum granulosum Anatomy 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108010025544 Bleomycin hydrolase Proteins 0.000 description 1
- 102100027058 Bleomycin hydrolase Human genes 0.000 description 1
- 108010032088 Calpain Proteins 0.000 description 1
- 102000007590 Calpain Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940093740 amino acid and derivative Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 210000000437 stratum spinosum Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
カリン(Chaenomeles sinensis)はバラ科の植物であり、果実は倒卵円形で黄色に熟し芳香を放つ。果実にはリンゴ酸、クエン酸、ショ糖、サポニン、プロアントシアニジンなどを含む。漢方ではカリン果実を縦割りにし乾燥させたものを用い、鎮咳、鎮痛、利水、疲労回復に有効とされる。
本発明の不全角化抑制剤はまた、ガロカテキン、エピガロカテキン、プロシアニジンB1またはプロシアニジンB2を有効成分として含む不全角化抑制剤についても提供する。
正常ヒト表皮角化細胞(NHEK(NB)、クラボウより入手)を5.0×104cells/cm2で播種した。24時間培養後、それぞれ以下の終濃度となるように培地に添加した。
(カルシトリオール)
・4.2E−7%(w/w)
・4.2E−6%(w/w)
(ガロカテキン)
・1.5E−4%(w/w)
・3.1E−4%(w/w)
(エピガロカテキン)
・1.5E−4%(w/w)
・3.1E−4%(w/w)
(プロシアニジンB1)
・2.9E−4%(w/w)
・5.8E−4%(w/w)
(プロシアニジンB2)
・2.9E−4%(w/w)
・5.8E−4%(w/w)
(カリン果実水抽出物)
・0.005%(w/w)(固形分濃度)
・0.01%(w/w)(固形分濃度)
(カリン果肉水抽出物)
・0.001%(w/w)(固形分濃度)
・0.002%(w/w)(固形分濃度)
・0.005%(w/w)(固形分濃度)
なお、カルシトリオールは、ビタミンD3の活性代謝体であり、陽性コントロールである。
Claims (7)
- カリンの果実、果肉、その抽出物、またはガロカテキン、エピガロカテキン、プロシアニジンB1およびプロシアニジンB2からなる群から選ばれる少なくともいずれかを有効成分として含む、不全角化抑制剤。
- カリンの果実または果肉の抽出物を、0.0001〜0.1%(w/w)の固形分濃度で含有する、請求項1に記載の不全角化抑制剤。
- 抽出溶媒が水である、請求項1または2に記載の不全角化抑制剤。
- ガロカテキンを1.0E−5〜1.0E−1%(w/w)の濃度で含有する、請求項1に記載の不全角化抑制剤。
- エピガロカテキンを1.0E−5〜1.0E−1%(w/w)の濃度で含有する、請求項1に記載の不全角化抑制剤。
- プロシアニジンB1を1.0E−5〜1.0E−1%(w/w)の濃度で含有する、請求項1に記載の不全角化抑制剤。
- プロシアニジンB2を1.0E−5〜1.0E−1%(w/w)の濃度で含有する、請求項1に記載の不全角化抑制剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019111985A JP7308513B2 (ja) | 2019-06-17 | 2019-06-17 | 不全角化抑制剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019111985A JP7308513B2 (ja) | 2019-06-17 | 2019-06-17 | 不全角化抑制剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020203844A true JP2020203844A (ja) | 2020-12-24 |
JP7308513B2 JP7308513B2 (ja) | 2023-07-14 |
Family
ID=73838656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019111985A Active JP7308513B2 (ja) | 2019-06-17 | 2019-06-17 | 不全角化抑制剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7308513B2 (ja) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08119843A (ja) * | 1994-10-25 | 1996-05-14 | T Hasegawa Co Ltd | メラニン抑制剤 |
JPH09315988A (ja) * | 1996-05-27 | 1997-12-09 | Shiseido Co Ltd | 抗酸化剤 |
JPH10330259A (ja) * | 1997-05-27 | 1998-12-15 | Kao Corp | 細胞間接着抑制剤 |
JP2000226309A (ja) * | 1999-02-02 | 2000-08-15 | Shiseido Co Ltd | 皮膚疾患の治療剤 |
JP2013032331A (ja) * | 2011-07-06 | 2013-02-14 | Kose Corp | 脂質産生抑制剤、皮脂産生抑制剤およびトリアシルグリセロール産生抑制剤 |
JP2014181187A (ja) * | 2013-03-18 | 2014-09-29 | Oriza Yuka Kk | ケラチノサイト減少抑制剤 |
JP2014181225A (ja) * | 2013-03-21 | 2014-09-29 | Kose Corp | 樹状突起負制御剤 |
JP6493899B1 (ja) * | 2018-05-24 | 2019-04-03 | 株式会社ジュポンインターナショナル | 抗ウイルス剤 |
-
2019
- 2019-06-17 JP JP2019111985A patent/JP7308513B2/ja active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08119843A (ja) * | 1994-10-25 | 1996-05-14 | T Hasegawa Co Ltd | メラニン抑制剤 |
JPH09315988A (ja) * | 1996-05-27 | 1997-12-09 | Shiseido Co Ltd | 抗酸化剤 |
JPH10330259A (ja) * | 1997-05-27 | 1998-12-15 | Kao Corp | 細胞間接着抑制剤 |
JP2000226309A (ja) * | 1999-02-02 | 2000-08-15 | Shiseido Co Ltd | 皮膚疾患の治療剤 |
JP2013032331A (ja) * | 2011-07-06 | 2013-02-14 | Kose Corp | 脂質産生抑制剤、皮脂産生抑制剤およびトリアシルグリセロール産生抑制剤 |
JP2014181187A (ja) * | 2013-03-18 | 2014-09-29 | Oriza Yuka Kk | ケラチノサイト減少抑制剤 |
JP2014181225A (ja) * | 2013-03-21 | 2014-09-29 | Kose Corp | 樹状突起負制御剤 |
JP6493899B1 (ja) * | 2018-05-24 | 2019-04-03 | 株式会社ジュポンインターナショナル | 抗ウイルス剤 |
Non-Patent Citations (3)
Title |
---|
ジュンサイエキスカタログ VER1.0 HS, JPN6017003800, 3 October 2012 (2012-10-03), JP, pages 0 - 22, ISSN: 0005044353 * |
石井 悠 ほか: "奈良県産カリンの抗老化作用及びその活性成分に関する検討", 日本薬学会第135年会要旨集, JPN6023016715, 5 March 2015 (2015-03-05), pages 28 - 208, ISSN: 0005044355 * |
粧技誌, vol. 47, no. 3, JPN6023016716, 2013, pages 216 - 220, ISSN: 0005044354 * |
Also Published As
Publication number | Publication date |
---|---|
JP7308513B2 (ja) | 2023-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102059453B1 (ko) | 배초향 잎 추출물을 유효성분으로 포함하는 피부장벽 강화 및 주름 개선용 화장료 조성물 | |
KR101490762B1 (ko) | 오크라 다당체를 유효성분으로 함유하는 화장료 조성물 | |
JP2008007411A (ja) | トランスグルタミナーゼ産生促進剤および表皮角化正常化剤 | |
KR101716680B1 (ko) | 자운고 발효 오일 및 이의 제조방법 | |
US9877915B2 (en) | Skin external composition for skin moisturization containing red yeast rice extract | |
CN106389175A (zh) | 一种含有玫瑰精油的营养保湿润肤水 | |
JP2011088845A (ja) | インボルクリン発現抑制剤 | |
JP2020535135A (ja) | 1,2,3,4,6−ペンタ−O−ガロイル−β−D−グルコースを含有する皮膚保湿用皮膚外用剤組成物 | |
KR101744889B1 (ko) | 항산화, 미백 및 주름개선 효과를 갖는 조성물 | |
JP6077560B2 (ja) | シロバナシマカンギク抽出物を含有する皮膚外用剤組成物 | |
JP5329830B2 (ja) | Scf分泌抑制剤、及び皮脂分泌抑制剤 | |
JP2009191039A (ja) | ヒアルロン酸合成酵素3mRNA発現促進剤、アクアポリン3mRNA発現促進剤、セリンパルミトイルトランスフェラーゼmRNA発現促進剤及びラミニン5産生促進剤 | |
KR20130138677A (ko) | 항노화 화장료 조성물 | |
KR20130035408A (ko) | 오매 추출물을 포함하는 피부 자극 완화용 조성물 | |
KR101896563B1 (ko) | 제주광나무 추출물을 함유하는 보습용 화장료 조성물 | |
KR20140093485A (ko) | 화장료 조성물의 제조방법 | |
JP7308513B2 (ja) | 不全角化抑制剤 | |
JP2009242310A (ja) | インボルクリン産生促進剤、トランスグルタミナーゼ−1産生促進剤、e−カドヘリン産生促進剤、及び毛穴目立ち軽減用皮膚外用剤 | |
KR20180117299A (ko) | 피부 개선용 조성물 | |
JP2012219031A (ja) | ラミニン5産生促進剤、インテグリンα6β4産生促進剤、皮膚基底膜正常化剤、皮膚損傷回復促進剤及びアクアポリン3mRNA発現促進剤 | |
KR20170051966A (ko) | 구골나무 추출물을 유효성분으로 포함하는 피부 미백용 조성물 | |
JP2009114146A (ja) | トランスグルタミナーゼ−1産生促進剤及びインボルクリン産生促進剤 | |
KR101533018B1 (ko) | 상지 추출물을 유효성분으로 함유하는 화장료 조성물 | |
KR101664878B1 (ko) | 삼채 분획물을 유효성분으로 함유하는 화장료 조성물 | |
KR102229902B1 (ko) | 페놀성화합물을 유효성분으로 하는 혼합 추출물을 포함하는 피부 보습 및 피부 장벽 개선 화장료 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190710 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220517 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230425 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230605 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230613 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230627 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7308513 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |